A Closer Look at 4 Analyst Recommendations For Elanco Animal Health
During the last three months, 4 analysts shared their evaluations of Elanco Animal Health (NYSE:ELAN), revealing diverse outlooks from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 2 | 2 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 1 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $19.75, with a high estimate of $23.00 and a low estimate of $16.00. Holding firm without variation, the current average remains at the previous average price target.
Analyzing Analyst Ratings: A Detailed Breakdown
A comprehensive examination of how financial experts perceive Elanco Animal Health is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| David Westenberg | Piper Sandler | Lowers | Neutral | $16.00 | $19.00 |
| Balaji Prasad | Barclays | Lowers | Overweight | $21.00 | $23.00 |
| David Westenberg | Piper Sandler | Raises | Neutral | $19.00 | $18.00 |
| Balaji Prasad | Barclays | Raises | Overweight | $23.00 | $19.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Elanco Animal Health. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Elanco Animal Health compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Elanco Animal Health's stock. This comparison reveals trends in analysts' expectations over time.
For valuable insights into Elanco Animal Health's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on Elanco Animal Health analyst ratings.
Discovering Elanco Animal Health: A Closer Look
Elanco Animal Health Inc is an animal health company that is engaged in innovating, developing, manufacturing, and marketing products for companion and food animals. Geographically, the company's operations are conducted globally and sell its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production. The company's product portfolio of approximately 200 brands.
Elanco Animal Health: Financial Performance Dissected
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Negative Revenue Trend: Examining Elanco Animal Health's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately -4.14% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 2.66%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Elanco Animal Health's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.52% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Elanco Animal Health's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.23%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Elanco Animal Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.95.
Analyst Ratings: What Are They?
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.